Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ram W Sabnis

Showing results (21-30 of 251) with videos related to

Pageof 26
Sort By:
ACS Medicinal Chemistry Letters|August 16, 2023
Novel Dihydroorotate Dehydrogenase Inhibitors for Treating Acute Myelogenous LeukemiaRam W Sabnis
ACS Medicinal Chemistry Letters|September 22, 2023
Novel Cyclopentathiophene Carboxamide Derivatives as PAFR Antagonists for Treating Ocular Diseases, Allergies, and Inflammation-Related DiseasesRam W Sabnis
ACS Medicinal Chemistry Letters|July 19, 2023
Novel Diaminopyrimidine Carboxamides as HPK1 Inhibitors for Treating CancerRam W Sabnis
ACS Medicinal Chemistry Letters|July 19, 2023
Novel Lactams as CBL-B Inhibitors for Treating CancerRam W Sabnis
ACS Medicinal Chemistry Letters|May 17, 2023
Novel Imidazotriazine Derivatives as IL-17 Modulators for Treating Inflammatory and Autoimmune DisordersRam W Sabnis
ACS Medicinal Chemistry Letters|November 19, 2025
Novel 1,4-Dihydro-2H-pyrano[3,4‑<i>c</i>]quinoline Compounds for Treating Bacterial Infections, Tuberculosis, or LeprosyRam W Sabnis
ACS Medicinal Chemistry Letters|July 16, 2025
Novel Amido Heteroaromatic Compounds as 17βHSD13 Inhibitors for Treating Liver Disease, Namely, NASHRam W Sabnis
ACS Medicinal Chemistry Letters|July 16, 2025
Novel Indole Derivatives as Serotonergic Psychedelic Agents for Treating Psychosis, Mental Illness, and CNS DisordersRam W Sabnis
ACS Medicinal Chemistry Letters|July 16, 2025
Novel N‑Substituted Indole Derivatives as Serotonergic Psychedelic Agents for Treating Psychosis, Mental Illness, and CNS DisordersRam W Sabnis
ACS Medicinal Chemistry Letters|May 14, 2025
Novel Isoxazolidines Derivatives as RIPK1 Inhibitors for Treating Neurodegenerative DiseasesRam W Sabnis
Pageof 26

Showing results (21-30 of 251) with videos related to

Sort By:
Pageof 26
ACS Medicinal Chemistry Letters|August 16, 2023
Novel Dihydroorotate Dehydrogenase Inhibitors for Treating Acute Myelogenous LeukemiaRam W Sabnis
ACS Medicinal Chemistry Letters|September 22, 2023
Novel Cyclopentathiophene Carboxamide Derivatives as PAFR Antagonists for Treating Ocular Diseases, Allergies, and Inflammation-Related DiseasesRam W Sabnis
ACS Medicinal Chemistry Letters|July 19, 2023
Novel Diaminopyrimidine Carboxamides as HPK1 Inhibitors for Treating CancerRam W Sabnis
ACS Medicinal Chemistry Letters|July 19, 2023
Novel Lactams as CBL-B Inhibitors for Treating CancerRam W Sabnis
ACS Medicinal Chemistry Letters|May 17, 2023
Novel Imidazotriazine Derivatives as IL-17 Modulators for Treating Inflammatory and Autoimmune DisordersRam W Sabnis
ACS Medicinal Chemistry Letters|November 19, 2025
Novel 1,4-Dihydro-2H-pyrano[3,4‑<i>c</i>]quinoline Compounds for Treating Bacterial Infections, Tuberculosis, or LeprosyRam W Sabnis
ACS Medicinal Chemistry Letters|July 16, 2025
Novel Amido Heteroaromatic Compounds as 17βHSD13 Inhibitors for Treating Liver Disease, Namely, NASHRam W Sabnis
ACS Medicinal Chemistry Letters|July 16, 2025
Novel Indole Derivatives as Serotonergic Psychedelic Agents for Treating Psychosis, Mental Illness, and CNS DisordersRam W Sabnis
ACS Medicinal Chemistry Letters|July 16, 2025
Novel N‑Substituted Indole Derivatives as Serotonergic Psychedelic Agents for Treating Psychosis, Mental Illness, and CNS DisordersRam W Sabnis
ACS Medicinal Chemistry Letters|May 14, 2025
Novel Isoxazolidines Derivatives as RIPK1 Inhibitors for Treating Neurodegenerative DiseasesRam W Sabnis
Pageof 26